BioNTech Results Presentation Deck

BNT111: Treatment Options Needed to Address CPI Failure in Advanced Melanoma Patients Melanoma Remains the Deadliest Skin Cancer Incidence + 50% Annual cases have increased by nearly 50% to over 287,0001.2 23 Deaths + 20% WHO predicts by 2025, number of deaths will increase by 20% 3 CPI R/R patients ~ 55% patients refractory to or relapse on CPI treatment, leaving them with limited treatment options4 ● ● ● Significant Opportunity to Improve on Standard of Care 5-year survival for metastatic melanoma still only 29.8% 5 Frontline immunotherapy with CPI induces durable responses in max. 45-50% of patients but with relatively short PFS4 CPI resistant/ refractory patients that fail to respond to CPI or relapse after CPI have an especially poor prognosis with survival as short as 6 months depending on risk factors Advanced CPI R/R melanoma is a high medical need population with highly unfavorable prognosis WHO, World Health Organization; CPI, check point inhibitor; R/R, refractory/resistant; mPFS, median progression free survival; ORR, Overall Response Rate; DoR, Duration of Response ¹https://www.melanomauk.org.uk/2020-melanoma-skin-cancer-report; 2Global Cancer Observatory - 2018 data from 'Cancer Today'; ³Global Cancer Observatory - projected 2025 data from 'Cancer Tomorrow'; 4Larkin J. et al. NEJM 2019;381(16):1535-1546; 5https://seer.cancer.gov/statfacts/html/melan.html Accessed August 06, 2021 BIONTECH

View entire presentation